Here, we show that high-dose ␥-irradiation accompanied with syngeneic bone marrow transfer can confer complete protection against glaucoma in a mouse model. Because bone marrow genotype was unaltered by this procedure, it was not the causative agent. The neuroprotection is robust and highly reproducible. Glaucoma-prone DBA͞2J mice received a single treatment at 5-8 weeks of age and were protected from glaucomatous retinal ganglion cell degeneration out to 14 months of age (oldest assessed). By 12-14 months, retinal ganglion cell degeneration is usually very severe and essentially complete in the majority of untreated DBA͞2J mice. To assess reproducibility, three groups of mice were treated at different times, and the results were essentially the same each time. Considering all experiments, the vast majority of treated mice had no detectable glaucomatous neurodegeneration. A beneficial effect of treatment including high-dose radiation is unprecedented, and we are not aware of any other neuroprotective effects this substantial. Because of the robust protective effect, this treatment offers another tool for studying mechanisms of neuroprotection.neuroprotection ͉ retinal ganlgion cell ͉ mouse model T he glaucomas are a group of complex neurodegenerative diseases. As a consequence of this neurodegeneration, glaucoma patients exhibit a loss of retinal ganglion cells (RGCs), characteristic changes in the visual field, and degeneration of the optic nerve (for review, see refs. 1 and 2). Glaucoma has traditionally been viewed as a pressure-induced neurodegeneration, in which deleteriously high intraocular pressure (IOP) results in optic nerve damage over time. As a consequence, all major existing glaucoma therapeutics aim to manipulate a single event, lowering IOP. However, it is increasingly clear that the glaucomas are multifactorial diseases, and IOP is not the only important factor. Many individuals who have high IOP do not develop glaucoma, when followed over long periods of time, whereas others develop optic nerve damage despite normal IOP values (3, 41). Clearly, elucidating additional factors determining RGC and optic nerve head susceptibility to glaucomatous neurodegeneration would facilitate a fuller understanding of disease processes and guide efforts toward improved therapeutics (5).Mouse studies are very useful for studying mechanisms contributing to multifactorial diseases and for testing potential treatments (6). Accordingly, our approach for studying the neurobiology of glaucoma has emphasized a naturally occurring mouse model of glaucoma, DBA͞2J mice. DBA͞2J mice develop an age-related form of hereditary glaucoma initiated by mutations in two genes, Tyrp1 and Gpnmb (7-9). Clinically, indications of DBA͞2J glaucoma are first evident by a pigmentdispersing iris disease that involves melanosomal (8, 9) and inflammatory (10) components. As dispersed pigment from the iris disease accumulates within the aqueous humor drainage sites, DBA͞2J mice develop an elevated IOP, which progressively insults RGCs and the...